Calcium Pyrophosphate Deposition (CPPD) Disease

NCT07005804 | Not Yet Recruiting

• 1 other identifier: RC-P00127
• Study Type: interventional
• Target: 137
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to describe the transcriptomic and metabolomic profile of patients with chronic Calcium Pyrophosphate Deposition (CPPD) compared to those with acute CPPD. The hypotheses are as follows :

• It is hypothesised that there is a transcriptomic and metabolomic signature of CPPD which explains why therapeutic responses to different anti-inflammatory treatments differ from one phenotype to another one
• It is hypothesised that the acute and chronic clinical phenotypes of CPPD have different clinical, biological and imaging characteristics, as well as a differing predisposition toward crystalline deposition and inflammatory pathway activation. The management of participants with chronic forms of the disease included in this research was modelled on the usual recommended management, including a biological workup, joint puncture, ultrasound and radiographic workup. Double-energy CT scans and transcriptomic and metabolomic analyses on plasma are not routine tests.

Conditions

Calcium Pyrophosphate Deposition Disease; Rheumatic Diseases

Keywords

Calcium pyrophosphate deposition disease; gene expression; acute clinical phenotype; chronic clinical phenotype; metabolic expression

Outcome Measures

Primary Outcomes (2)

• Transcriptomic profile

  -Quantitative transcriptomic profiling (expression of the genes involved) and qualitative profiling (analysis of the sequence of variants expressed)

  2 weeks

• Metabolomic profile

  \- Metabolomic profile: quantitative assessment of the metabolites involved in each phenotype, then qualitatively grouped by activated metabolic pathway

  2 weeks

Study Arms (1)

Patients with a chronic CPPD

EXPERIMENTAL

Patients with diagnosis of chronic calcium pyrophosphate crystal arthritis (either acute recurrent or persistent arthritis), meeting the 2023 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria, after evaluation by a rheumatologist from the rheumatology department.

Genetic: transcriptomic and metabolomic analysis

Interventions

transcriptomic and metabolomic analysis GENETIC

Venous blood samples for transcriptomic and metabolomic analysis will be taken in 3 x 4 mL ethylenediaminetetraacetic acid (EDTA) tubes and stored immediately at 4°C, before being cryopreserved at -80°C in 500 μL aliquots of plasma. In addition, for transcriptomic analysis, a sample will also be taken in a Paxgen RNA tube cryopreserved at -80°C.

Patients with a chronic CPPD

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Cases included in the COLCHICORT cohort (NCT03128905), for whom this was the first acute episode of CPPD
• Patients affiliated to the French social security system
• Age ≥ 65 years
• Diagnosis of chronic CPPD (recurrent acute or persistent arthritis), meeting ACR/EULAR 2023,11 classification criteria after evaluation by a rheumatologist in the rheumatology department
• Progression of CPPD rheumatism for at least 3 months and still active CPPD rheumatism, defined by a visual analogue scale (VAS) of disease activity ≥ 40 and/or presentation of at least 1 crisis over the last 3 months
• Glomerular Filtration Rate (GFR) in Chronic Kidney Disease Epidemiology (CKD EPI Collaboration) ≥ 30ml/min/1.73m2
• Signed written consent for study participation

You may not qualify if:

• Missing data concerning transcriptomic and metabolomic analyses.
• Opposition
• History of gout or presence of monosodium urate (MSU) crystals on joint fluid,
• Cognitive decline (confusion and neurodegenerative diseases)
• Inability to provide informed consent and disease VAS
• Patient under guardianship or curatorship

Sponsors & Collaborators

• Lille Catholic University: lead

Study Sites (1)

Hôpital Saint-Philibert (GHICL)

Lomme, 59160, France

Location

MeSH Terms

Conditions

Chondrocalcinosis; Rheumatic Diseases

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Crystal Arthropathies; Connective Tissue Diseases; Skin and Connective Tissue Diseases

Study Officials

• Charlotte JAUFFRET

  Rheumatology Department - Hôpital Saint-Vincent - GHICL

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Marie Paule LEBITASY

CONTACT

+333 20 22 57 41; Lebitasy.Marie-Paule@ghicl.net

Marie DESOLERE

CONTACT

+33 320225931; desolere.marie@ghicl.net

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: The PYC-OMIC study is a prospective, single-centre, cross-sectional, comparative study of chronic versus acute forms of CPPD. It is an interventional study with minimal risks and constraints for chronic forms recruited prospectively. Acute forms are included retrospectively.

Study Record Dates

• First Submitted: May 26, 2025
• First Posted: June 5, 2025
• Study Start: October 1, 2025
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): November 1, 2027
• Last Updated: June 5, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)